Evolving paradigms in digestive oncology: highlights and reflections from ASCO 2025
Revista Portuguesa Oncologia · 2025
DOI: 10.24875/rpo.25000013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Portuguesa Oncologia, 2025. Verfasst von Teresa Fraga.
Abstract (Originalsprache)
Trastuzumab deruxtecan (T-DXd) versus ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): primary analysis of the randomized, phase 3 DESTINY-Gastric04 (DG04) studyDG04, which evaluated T-DXd against the current standard of care combination of RAM and PTX in patients with unresectable or metastatic HER2+ gastric or gastroesophageal junction (GEJ) adenocarcinoma who had progressed on prior trastuzumab-based therapy.T-DXd demonstrated a statistically significant improvement in overall survival and met its primary endpoint, with a reduction of the risk of death of 30% (14.7 vs. 11.4 months; hazard ratio [HR] 0.70; p = 0.0044).This trial highlights the growing relevance of antibody-drug conjugates in gastrointestinal cancers.However, although most of the adverse events related to the treatment were manageable, the 13.9% incidence of interstitial lung disease warrants caution, underscoring the need for close monitoring and patient education.DG04 is a landmark study that will likely influence second-line treatment standards of HER2positive gastric or GEJA.
Zitieren
APA
Fraga, T. (2025). Evolving paradigms in digestive oncology: highlights and reflections from ASCO 2025. Revista Portuguesa Oncologia. https://doi.org/10.24875/rpo.25000013
Vancouver
Fraga T. Evolving paradigms in digestive oncology: highlights and reflections from ASCO 2025. Revista Portuguesa Oncologia. 2025. doi:10.24875/rpo.25000013
BibTeX
@article{Fraga2025,
author = {Fraga, Teresa},
title = {Evolving paradigms in digestive oncology: highlights and reflections from ASCO 2025},
journal = {Revista Portuguesa Oncologia},
year = {2025},
doi = {10.24875/rpo.25000013}
}
EUVIMED